Wellstar International, Inc., through its subsidiary, Trillennium Medical Imaging, Inc., engages in developing and licensing the use of advanced thermal imaging technology in the consumer healthcare and veterinary markets in the United States. The company places cameras in hospitals, clinical, and care facilities based on its infrared technology and software. Its technology enables a diagnostic screening procedure for early breast cancer detection; differential diagnosis of pain dysfunctions, such as reflex sympathetic dystrophy, neuromuscular skeletal syndromes, and neurological disorders; and detection of pressure ulcers; deep tissue injuries; and bed sores, as well as orthopedic applications. Wellstar International markets its products to university research centers, hospitals, multidisciplinary physician practices, pain centers, care facilities, home health care, and rehabilitation centers. The company was founded in 1997 and is based in Holland, Ohio.

Trillennium Medical Imaging, Inc. (TMI) is dedicated to placing cameras for a monthly charge in hospitals, clinical and long care facilities throughout the United States. The company’s current competitive advantage is derived from the state of the art technology of the camera and software it is utilizing, combined with an intimate knowledge and relationships in the markets. It plans to grow in these markets by expanding its imaging capabilities by the constant acquisitions of new imaging technologies.

The TMI Infrared Technology and software is approved by the FDA as an Adjunctive Diagnostic screening procedure for early breast cancer detection, differential diagnosis of pain dysfunctions, (such as Reflex Sympathetic Dystrophy, Neuromuscular Skeletal Syndromes and Neurological disorders), detection of pressure ulcers, deep tissue injuries, and bed sores, as well as orthopedic applications. This screening modality provides a differential diagnosis to justify additional screening procedures to ensure successful patient outcome assessment. Thermal Imaging is a low cost, non-contact, non-radioactive diagnostic screening procedure designed for clinical evaluation. In addition thermal imaging provides an ability to track the progress of therapies being utilized in a low cost, non-invasive manner.

The TMI Infrared Technology fills a need that currently exists in diagnostic medicine today. Thermal imaging provides information that is specific to the physiological and functional activity in the body. This information becomes invaluable in that conventional diagnostic screening utilizes tests such as X-Ray, MRI and CT Scans. All aspects of these tests are concerned with the anatomical and structural problems of the body. Many problems arise from not combining both diagnostic modalities of structure and physiology, in that people are missed diagnosed and considered healthy and well when the physiological information provides an earlier outcome or risk assessment of future health predictors than the structural modalities.

Major markets such as University Research Centers, hospitals, multidisciplinary physician practices, pain centers, long term care facilities, home health care, and rehabilitation centers support the need for this type of screening modality.

In summary, Trillennium Medical Imaging has created an innovative new business model that gives it early market advantage.

Why this is a hot stock

- Trillennium Medical Imaging sees the future of infrared imaging moving to critical positions in early phase disease detection and monitoring. Although currently not a diagnostic modality, infrared analysis still provides key information in health monitoring. The development of objective data analysis and proof of efficacy will catapult infrared detection to key positions and prominence. Trillennium’s completed research project conducted at Duke University for early detection of tissue breakdown, provides the initial data demonstrating the TMI Systems ability to detect damage prior to visible evidence. This capability – in a non-contact device – will save patients from potential disabling conditions, as well as generate a sizeable cost-savings in health care.

- Trillennium Medical has begun investigating the use of infrared detection in early stage pressure ulcer development. Trillennium is proposing a unique approach for early detection of tissue changes that will significantly impact the wound care market. TMI is in the initial phase for design and application of a new imaging device that incorporates software and data collection that is separate and apart from its current clinical markets.

- Trillennium Medical Imaging will be ideally positioned to provide a cost-effective, non-contact method to identify the presence of early or existing tissue damage. The next step for TMI is to implement the system within the marketplace with a Beta Test. TMI believes that the Beta Test will begin the early part of 2010 as we are currently in discussions.

- Each year the government spends on average over $3 billion on wound treatment and care for pressure sores and bedsores. Insurance companies pay out millions annually for this same treatment, directly affecting premiums to increase annually for healthcare facilities. Inflationary effects add to this escalation.

Wellstar International Inc.
6911 Pilliod Road
Holland, OH 43528

Phone: 419-865-0069
Fax: 419-867-0829
www.wellstar.us